4. SARS-CoV-2 Antigens and Antibodies
The main antigens studied in SARS-CoV-2 humoral response are structural proteins Spike (S) and Nucleocapsid (N). It is observed that S protein can be detected entirely, or by means of its subunits 1 (S1) and 2 (S2). Another antigen related to it is the Receptor-binding domain (RBD), which lies at S1 [
20].
Before discussing the antigens and immunoglobulin (Ig) classes, it is relevant to highlight that, in general, the detection of antibodies is a limited tool for diagnosis. In some cases, the detection of IgM or IgG may point out acute or chronic infection, respectively [
21]. However, the pathophysiology of the disease should be well-known, so the results will not be masked by vaccine response or immunologic window. This is why detecting the pathogen itself, its nucleic acid, or antigens usually are considered a gold standard [
22,
23]. Concerning SARS-CoV-2, the gold standard for diagnosis is the detection of viral RNA by RTq-PCR. Considering the unprecedented number of cases, the use of antigen-detection was a strategy to support COVID-19 diagnosis, proving the presence of viral antigens in nasopharyngeal samples [
23,
24].
The abundance of S and N antigens in the course of SARS-CoV-2 infection substantiates its use in immunoassays, regardless of the aim being to detect the antigen or the antibodies [
25]. It must be noted that there is a difference in the positivity dynamics of each antigen. Anti-N antibodies become positive, on average, two days earlier than anti-S antibodies, but they have a shorter half-life. In fact, anti-S antibodies are detectable for longer periods. Thus, it might explain decreased sensitivity of N-based assays when samples collected at longer moments are tested [
26].
Antigen-detection assays are often based on lateral-flow immunoassays using nasopharyngeal samples, where the viral load is concentrated. The use of two antigens increases test sensitivity [
23]. In fact, testing nasopharyngeal samples in an N-chemiluminescence enzymatic immunoassay provided satisfactory concordance with gold-standard RT-qPCR [
27]. To achieve high sensitivity and specificity, antigen-detection tests should be conducted up to seven days after infection [
28]. However, a fluorescent ELISA to detect the Nucleocapsid antigen in serum was developed, as well as an ELISA to capture the Spike protein [
7,
29]. To improve clinical-laboratory testing, automated assays to detect SARS-CoV-2 antigens are available as well, and correlated well with RT-qPCR results. In that case, specificity may reach 100%, while sensitivity levels are related to the positivity threshold established [
30].
Considering antibody-detection assays, it should be understood that using S and N proteins might increase the sensitivity, providing more epitopes for the antibodies to bind. On the other hand, it can increase the cross-reactivity. Thus, subunit antigens, such as RBD, have been used to assess SARS-CoV-2 immune response in a more specific way [
25]. This antigen is undeniably important, since it mediates the interaction between the virus and the Angiotensin-converting enzyme 2 (ACE-2), used as receptor. However, there are studies reporting neutralizing antibodies directed to the N-terminal domain (NTD) of S1 subunit, highlighting that this is another relevant antigen to be studied [
31,
32].
Envelope (E) and Membrane (M) are other structural proteins but, due to their small molecular size, usually they do not provide a robust humoral response [
20]. However, recent studies provide new data about it. Anti-Membrane antibodies were detected in COVID-19 patients up to 12 months after infection and Envelope-IgM has shown a less accentuated decrease than S1-IgM [
33]. Thus, tests detecting Ig against different antigens could be employed to distinguish natural and vaccine-induced immune responses, as long as the subjects were vaccinated with subunit vaccines.
Considering Ig classes, the curve of anti-SARS-CoV-2 antibodies differs from most infections, making it difficult to predict acute or chronic/memory immune responses. Usually, IgM antibodies increase during the first two weeks of infection; hence, its “acute marker” characteristic was coined. Afterwards, IgM antibodies decay while IgG titers increase [
21]. In COVID-19, the first reports suggested the same pattern, but more recent studies point to a different one, where IgM and IgG antibodies increase concomitantly since the beginning of infection, being detected as early as three days following infection [
34,
35]. Even more curious is the fact that IgA would be a better marker of acute infection than IgM, increasing in the first days following infection and maintaining its titers for up to 30 days, whereas IgM would decay after 15 days. Also, combined detection of IgA/IgG would confer more sensitive results than IgM/IgG. Another way to increase the sensitivity of immunoassays is to use anti-Ig detection antibodies, which will reveal the presence of the whole antibody content of the sample, regardless of the Ig class [
36].
IgG is related to immunologic memory and, in some cases, it can be detected years after the infection or vaccination [
21]. However, serologic studies suggest that anti-SARS-CoV-2 IgG would decrease six to eight months after infection [
37,
38]. Although the vaccination campaigns are recent and studies to elucidate the immunologic memory conferred by them are still ongoing, there are reports showing persistence of antibodies up to six months after vaccination [
39,
40]. It is worth emphasizing that seropositivity for anti-SARS-CoV-2 IgM and IgG occurs about the same time following infection.
Figure 1 represents the structural antigens used in SARS-CoV-2 immunoassays and the antigen or antibody detection curve expected in SARS-CoV-2 immune response.
Figure 1. (A) SARS-CoV-2 structural antigens, used for immunoassays. Nucleocapsid and Spike proteins are the most abundant antigens, therefore, they are used for improved sensitivity. Antigen-subunits, as S1 and S2, or RBD and NTD, can provide more specific results. (B) The expected IgM/IgG curves following exposure to antigen through natural infection or vaccination. The maturation of immune response usually leads to initial IgM induction and, while titers of this antibody class decrease, IgG titers increase and persist for longer periods, which varies according to the pathogen considered. Below it, kinetics of SARS-CoV-2 antigens and antibodies detection is represented. Differently from the expected, titers of IgA, IgM, and IgG antibodies increase in parallel. The time to achieve seronegativity and the particularities of vaccine-induced humoral response are still being elucidated (figure created with BioRender).
The sole presence of antibodies following natural infection should be cautiously analyzed, especially when the patient is individually considered, because it does not prove an antibody functionality, predicting protection [
2]. So far, high antibodies quantities were observed in severe COVID-19 cases [
41,
42].
For some infectious diseases, the specificity of the immune response can predict better or worse prognostic. Some studies following COVID-19 patients suggested a worst prognosis when a Nucleocapsid was observed instead of a Spike-biased immune response. However, others could not observe any difference between the antigens recognized and the severity of the disease [
41,
42]. Similarly, the impact of the kinetics of humoral response was related to a better or worst clinical condition. Hashem et al. [
43] reported that an early seroconversion correlated with fatality, but Lucas et al. [
44] observed a delayed antibody response in deceased patients. Meanwhile, the study of Van Elslande et al. [
17] did not indicate significant differences in time to critical and non-critical patients to seroconvert. Disagreeing results suggest that further studies are necessary to elucidate these aspects and support the interpretation of ELISA results.
Secretory IgA, locally produced at mucosal sites, are chief to control mucosal infections, but the role of seric IgA has been up for debate. It may help control the inflammation, but authors disagree about its capacity to activate the complement system and opsonize pathogens [
45,
46,
47]. Regarding COVID-19, there is evidence that seric IgA acts on early virus neutralization [
48]. Fedele et al. [
49] observed that early IgA response was seen in patients with less severe COVID-19, but Portilho et al. [
42] could not relate increased IgA response to mild patients response. Despite the disagreeing results of different studies, the detection of seric IgA could reflect secretory IgA. There is evidence that naïve B cells activated in the mucosa can be home to the marginal zone of the spleen, so IgA triggered against mucosal pathogens could be released in the bloodstream and contribute to control the infection [
50,
51].
Finally, even though antibody-detection assays are limited to diagnosing the current infection, these technologies are still relevant, especially to select plasma donors, vaccine studies, and epidemiological monitoring [
2].